AH 111585

12/01/2014 - "Our study suggests tumor [(18)F]fluciclatide retention is unrelated to tumor perfusion, supporting use of late (60-min) imaging protocols in patients."
12/01/2014 - "The study rationale was to perform a preliminary evaluation of the relationship between tumor [(18)F]fluciclatide uptake and perfusion by [(15)O]H2O PET. "
12/01/2014 - "Voxel-by-voxel maps of [(18)F]fluciclatide delivery strongly correlated with [(15)O]H2O-based perfusion (p < 10(-4) tumor, 1,794 ± 1,331 voxels). "
10/01/2014 - "Tumors from all 18 patients demonstrated measurable [(18)F]fluciclatide uptake. "
10/01/2014 - "Eighteen evaluable patients with solid tumors ≥2.0 cm underwent [(18)F]fluciclatide PET/CT. "

06/01/2008 - "The biodistribution of 18F-AH111585 was assessed in 18 tumor lesions from 7 patients with metastatic breast cancer by PET, and the PET data were compared with CT results. "
06/01/2008 - "Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients."
12/01/2011 - "Quantification of receptor-ligand binding with [¹⁸F]fluciclatide in metastatic breast cancer patients."
12/01/2011 - "To this aim, we employed dynamic positron emission tomography (PET) data obtained from breast cancer patients with metastases, studied with the α(v)β(3/5) integrin receptor radioligand [(18)F]fluciclatide. "
06/01/2008 - "18F-AH111585 designed to bind the alpha v beta3 integrin is safe, metabolically stable, and retained in tumor tissues and detects breast cancer lesions by PET in most anatomic sites."

06/01/2008 - "All 18 tumors detected by CT were visible on the 18F-AH111585 PET images, either as distinct increases in uptake compared with the surrounding normal tissue or, in the case of liver metastases, as regions of deficit uptake because of the high background activity in normal liver tissue. "
12/01/2011 - "To this aim, we employed dynamic positron emission tomography (PET) data obtained from breast cancer patients with metastases, studied with the α(v)β(3/5) integrin receptor radioligand [(18)F]fluciclatide. "
12/01/2014 - "Tumor binding potential (k 3/k 4 ratio) of [(18)F]fluciclatide tumor was 5.39 ± 1.46, consistent with previous studies in breast cancer metastases. "

10/01/2014 - "[(18)F]Fluciclatide PET imaging was well tolerated and demonstrated favorable characteristics for imaging αvβ3 and αvβ5 expression in melanoma and RCC. "
12/01/2014 - "Patients with non-small cell lung cancer and melanoma underwent dynamic imaging with arterial sampling following injection of [(15)O]H2O and [(18)F]fluciclatide. "
10/01/2014 - "[¹⁸F]fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αvβ 3 and α vβ 5 integrins."
10/01/2014 - "Our aim was to use [(18)F]fluciclatide (formerly known as [(18)F]AH111585) for PET imaging of angiogenesis in melanoma and renal tumors and compare with tumor integrin expression. "

08/01/2014 - "Human aneurysmal aortic tissue, collected during elective resection of abdominal aortic aneurysm (AAA) of asymptomatic patients, was investigated in vitro by means of autoradiography with [(68)Ga]CRP-binder targeting C-reactive protein, [(11)C]DAA1106 targeting translocator protein (18 kDa), [(11)C]D-deprenyl with unknown target receptor, [(11)C]deuterium-L-deprenyl targeting astrocytes, [(18)F]fluciclatide targeting integrin αVβ3, [(68)Ga]IMP461 and bi-specific antibody TF2 052107 targeting carcinoembryonic antigen, [(18)F]F-metomidate targeting mitochondrial cytochrome P-450 species in the adrenal cortex, and [(18)F]vorozole targeting aromatase. "